Abstract
The potential for hormonal intervention in cancer was identified as early as 1895, even before the concept of hormones was established. Indeed, we know that the first hormone was discovered only in 1902 (secretin, by Bayliss and Starling). The Scottish surgeon Beatson performed a bilateral ovarectomy in a young woman with an enormous cancer of the breast. The tumor regressed spectacularly. Subsequently, other hormonal actions on cancer were made possible (prostate, endometrial, thyroid), and it was extablished that this action was modulated by the presence of hormonal receptors in the cancerous tissue [1] (Figs. 1,2).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
McGuire WL (1978) Hormone receptors: their role in predincting prognosis and response to endocrine therapy. Semin Oncol 5:428 – 433
Levin DL, Connelly RR, Devesa SS (1981) Demographic characteristics of cancer of the pancreas: mortality, incidence, and survival. Cancer 47:1456–1468
Lin RS, Kessler II (1981) A multifactorial model for pancreatic cancer in man. Epidemiologie evidence. JAMA 245:147–152
Clemente F, Scemama JL, Ruellan C, Estival A (1986) Human pancreatic cancer cells in culture: an approach to their hormonal regulation and differentiation. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 28–39
Benz C, Hollander C, Miller B (1986) Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 31:2276–2281
Serrano MJ, Liebow C, Reilly C, Schally AV (1988) LH-RH analog causes direct inhibition of growth of pancreatic cancer cells in culture. Pancreas 3:617
Lacaine F, Houry S, Clough K, Lointier P, Huguier M (1986) Is pancreatic tumor growth inhibited by sex hormones? An experimental study in hamster. Eur Surg Res 18:22
Sumi C, Longnecker DS, Roebuck BD, Brinck-Johnsen T (1989) Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res 49:2332–2336
Longnecker DS(i986) Experimental pancreatic cancer: role of species, age, sex and diet. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 78–92
Greenway B, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R (1982) The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg 69:595–597
Kyriazis AP, Kyriazis AA (1986) Transplantation and biological behavior of human pancreatic cancer in the nude mouse. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 93 –104
Redding TW, Schally AV (1984) Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypotalamic hormones. Proc Natl Acad Sci USA 81:248 – 252
Szende K, Srkalovic G, Schally AV, Lapis K, Groot K (1990) Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer 65:2279 – 2290
Greenway B, Igbal MJ, Johnson PL, Williams R (1981) Oestrogen receptor proteins in malignant and fetal pancreas. Br. Med J 283:751 – 753
Satake K, Yoshimoto T, Mukai R, Umeyama K (1982) Estrogen receptors in 7,12-dimethylbenz(a)-anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. Clin Oncol 8:49 – 54
Benz C, Wisnitzer I, Benz C (1984) Steroid binding and cytoxicity in cultured human pancreatic carcinomas. Prog Cancer Res Ther 31:223–228
Pousette A, Appelgren L, Carlstrom K, Skoldefors H, Wilking N, Theve NO (1984) Purification and characterization of an estradiol-17-b-finding macromolecule in rat pancreas. Acta Chem Scand B38:407 – 414
Lointier P, Pezet D, Ferrier C, Chipponi J, Saez S (1988) Rôle des sites spécifiques de liaison du tamoxifène (TAM) et distincts des récepteurs aux oestrogènes (RE) dans l’inhibition de la croissance in vitro d’un adénocarcinome pancréatique humain (MIA PaCa-2) par le TAM. Gastroenterol Clin Biol 11:264
Corbishley TP, Igbal MJ, Johnson PJ, Williams R (1984) Progesteone receptors in malignant and foetal pancreatic tissue. IRCS Med Sci 12:575–576
Grenway BA (1987) Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? Br J Surg74:441–442
Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R (1986) Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 57:1992–1995
Andren-Sandberg A (1989) Androgen influence on exocrine pancreatic cancer. Int J Pan-creatology 4:363 – 369
Greenway BA, Iqbal MJ, Johnson PJ, Williams R (1983) Low serum testosterone concentrations in patients with carcinoma of the pancreas. Br J Med J 286:93–95
Robles-Diaz G, Diaz-Sanchez V, Morales M, Gulias A, Fernandez Del Castillo C (1990) Le rapport testosterone/dihydrostestosterone (T/DHT) et testosterone/androstenedione (T/A) dans le cancer du pancreas. Gastroenterol Clin Biol 14: A8
Friess H, Buchler M, Kiesel L, Kruger M, Beger HG (1991) LH-RH receptors in the human pancreas. Int J Pancreatol 10:151 –159
Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV (1989) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521–528
Theve NO, Pousette A, Carlstrum K (1983) Adenocarcinoma of the pancreas — a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 115:244–248
Tonnesen K, Kamp-Jensen M (1986) Antioestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol 12:69 – 70
Crowson MC, Dorbella A, Rolfe EB, Fielding JWL (1986) A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 12:335–336
Wong A, Chan A, Arthur K (1987) Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 71:749 – 750
Scheithauer W, Kornek G, Haider K, Depisch D (1990) Unresponsiveness of pancreatic adeno-carcinoma to anti-oestrogen therapy. Eur J Cancer 26:851–852
Gonzales-Marcena D, Ibarra-Olmos MA, Garcia-Carrasaco F, Gutierrez-Samperio C, Comaru-Schally AM, Schally AV (1989) Influence of (D-Trp6)-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43:313–317
Frieb H, Buchler M,Kruger M, Beger HG (1992) Treatment of duct carcinoma of the pancreas with the LH-RH analog buserelin. Pancreas 7:516–521
Keating JJ, Johnson PJ, Cochrane MG et al (1989) A prospective randomized controlled-trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60 : 789–792
Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B (1990) Tamoxifen therapy in unresect able adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 77:725–730
Huguier M, Samama G, Testart J et al. (1991) L’hormonothérapie dans les cancers du pancréas exocrine: une étude de l’AURC, l’ARC et de l’ARCIF Gastroenterol Clin Biol 15:169
Mainz DL, Black O, Webster PD (1973) Hormonal control of pancreas growth. J Clin Invest 52:2300–2304
Dembinski AB, Johnson LR (1980) Stimulation of pancreatic grow secretin, coerulein and pentagastrin. Endocrinology 106:323 – 328
Balas D, Senegas Balas F, Pradayrol (1985) Long-term comparative effect of chlecystokinin and gastrin on mouse stomach, antrum, intestine, and exocrine pancreas. Am J Anat 174: 27–43
Lehy T, Dubrasquet M, Brazeua P, Bonfils S (1982) Inhibitory effect of prolonged administration of long-acting somatostatin on gastrin-stimulated fundic epithelial cell growth in the rat. Digestion 24:246–255
Morisset J, Genki P, Lord A, Solomon TE (1982) Effects of chronic administration of somatostatin on rat exocrine pancreas. Regul Pept 4:49–58
Towsend CM, Singh P, Thompson JC (1986) Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 91:1002–1006
Liehr RM, Melnykovych G, Solomon TE (1990) Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA Pa-Ca-2. Gastroenterology 98:1666 –1674
Smith JP, Solomon TE, Bagheri S, Kramer S (1990) Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 11:1377–1384
Pour PM (1986) Experimental pancreatic cancer in hamsters: etiology, comparative pathology and immunology. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 60–77
Longnecker DS (1991) Hormones and pancreatic cancer. Int J Pancratol 9:81–86
Douglas BR, Woutersen RA, Jansen JBMJ, Dejong AJL, Rovati LC, Lamers CBHW (1989) Influence of cholecystokinin antagonist on the effects of cholecystolinin and bombesin on aszaserine-induced lesions in rat pancreas. Gastroenterology 96:462–469
Nagain C, Roze C (1991) Les récepteurs de la cholecystokinine. Gastroenterol Clin Biol 15:735–743
Estival A, Clémente F, Ribet A (1981) Adenocarcinoma of the human exocrine pancreas: presence of secretin and caerulein receptors. Biochem. Biophys Res Common 102: 1336–1341
Edwards BF, Redding TW, Schally AV (1989) The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa). Int J Pancreatol 5:191 - 201
Axelson J, Ihse I, Hakanson R (1992) Pancreatic cancer: the role of cholecystokinin? Scand J Gastroenterol 27:993-998
Takacs T, PAP A (1991) Perspective of CCK antagonists in pancreatic research. Int J Pancreatol 10:1-8
Maani R, Townsend CM, Gomez G, Thompson JC, Singh P (1988) A potent CCK receptor antagonist (L-364, 718) inhibits the growth of human pancreatic cancer in nude mice. Gastroenterology 94-274 (abstract)
Stace NH, Palmer TJ, Vaja S, Dowling RH (1987) Longterm pancreticobiliary diversion stimulates hyperplastic and adenomatous noduels in the rat pancreas: a new model for spontaneous tumour formation. Gut 28 [Suppl] : 265 - 268
Scemama JL, De Vries L, Pradayrol L, Seva C, Tronchere H, Vaysse N (1989) Cholecystokinin and gastrin peptides stimulate ODC activity in a rat pancreatic cell line. Am J Physiol 256:6846-850
Townsend CM Jr, Franklin RB, Watson LC, Glass EJ, Thompson JC (1981) Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 32:228 - 229
Howatson AG, Carter DC (1987) Pancreatic carcinogenesis: effect of secretin in the hamster-nitrosamine model. J Natl Cancer Inst 78:101-105
Poston GJ, Yao CZ, Upp JR, Alexander RW, Townsend CM, Thompson JC (1988) Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo. Pancreas 3:439 - 443
Lhoste EF, Longnecker DS (1987) Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas. Cancer Res 47:3273–3277
Alexander RW, Upp JR, Poston GJ, Townsend CM, Singh P, Thompson JC (1988) Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice. Pancreas 3:297–302
Viguerie N, Tahiri-Jouti N, Ayral AM et al. (1988) Somatostatine et prolifération cellulaire-antagonisme somatostaine-EGF sur une lignée pancréatique tumorale de rat AR4-2J. Gastroenterol Clin Biol 12: A116
Hajri A, Aphrahamian M, Balboni G, Koenig M, Damge C (1990) Effet de la somatostatine-retard, la sandostatine, sur une tumeur pancréatique acinaire transplatée chez le rat en fonction du stade de la croissance tumorale. Gastroenterol Clin Biol 14: A56
Poston GJ, Lawrence JP, Singh P, Towsend CM, Thompson JC (1988) Inhibition of growth of human pancreatic cancer in vivo hy somatostatin and tamoxifen. Br J Surg 75:1257
Hierowski MT, Liebow C, Dusapin K, Schally AV (1985) Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 179:252–256
Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JG, Lamberts SW (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95 : 760–763
Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R (1992) Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 69:648–650
Abruzzese JL, Gholson CF, Daugherty K, Larson E, Dubrow R, Berlin R, Levin B (1992) A pilot clinical trial of cholecystokinin receptor antagonist MK 329 in patients with advanced pancreatic cancer. Pancreas 7:165–171
Korc M (1986) Epidermal growth factor receptor: its role in pancreatic cancer. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 40–47
Korc M (1991) Growth factors and pancreatic cancer. Int J Pancreatol 9:87–91
Glinsmann-Gibson BJ, Korc M (1991) Regulation of transforming growth factor-alpha mRNA expression in T3M4 human pancreatic carcinoma cells. Pancreas 6:162–149
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Caroli-Bosc, F.X., Hastier, P., Harris, A.G., Gaudray, P., Balas, D., Delmont, J.P. (1994). Receptors and Their Modulation. In: Pederzoli, P., Cavallini, G., Bassi, C., Falconi, M. (eds) Facing the Pancreatic Dilemma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79167-3_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-79167-3_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-58284-7
Online ISBN: 978-3-642-79167-3
eBook Packages: Springer Book Archive